Back to the main directory
Company Analysis / Equity
- Maintaining Our Fair Value Estimate for Takeda After Solid 2Q for Key Drugs Entyvio and Ninlaro by Morningstar
- Structural Trends Likely to Outweigh Brexit for Xero by Morningstar
- Brocade’s Investor Day Offers Less Optimistic Outlook; Focus Shifts to Expense Control by Morningstar
- IAG consists of well-known brands, with concentrated exposure to mature general insurance markets. by Morningstar
- Consorcio Aristos' 2Q Results Show Continued Expansion; Shares Overvalued by Morningstar
- The dual-brand customer-focused strategy supports earnings growth despite soft policyholder growth. by Morningstar
- Electric Vehicles Offer No Support for Slowing U.S. Electricity Demand Growth by Morningstar
- Increasing Ormat's Fair Value Estimate on Margin Improvement and Strong Growth Pipeline by Morningstar
- Wolseley Inching, but Not Quickly Enough, Towards a Concentrated Portfolio; Shares Overvalued by Morningstar
- Yum China offers a direct play on Chinese consumption and underappreciated capital allocation story. by Morningstar
- Capital One's Third Quarter: Charge-Offs Increase, but So Do Income and Loan Yield by Morningstar
- U.S. Elections Add Uncertainty to Healthcare Stocks, but Unlikely to Cause Major Fair Value Changes by Morningstar
- U.S. Steel Makers to Benefit From Trump Stimulus but Market Draws Long Bow With Optimism for Miners by Morningstar
- Strong Competition Expected as Generics Eye Axiron Market Share; Lowering FVE to AUD 0.40 per Share by Morningstar
- Near-term growth will be limited, but we think the new Aviva will be a safer insurance company. by Morningstar
- Relaunching Coverage of Pembina; Raising Fair Value Estimate Slightly by Morningstar
- Hilton's brand continues to strengthen amid a challenging industry environment. by Morningstar
- CSX Preserves Respectable Margins Despite 21% Plunge in Coal Volume by Morningstar
- Outlook Unchanged for Hormel After On-Track 4Q Results; Shares Slightly Rich by Morningstar
- Despite EpiPen and Generic Market Challenges, Mylan Posts Decent Third Quarter by Morningstar
- Weaker Chinese demand for base metals will limit returns on First Quantum's large growth potential. by Morningstar
- Offshore Pathology Business Booms for Sonic Healthcare; Raising Fair Value Estimate to AUD 24 by Morningstar
- Crude-Market Fundamentals Continue to Tighten, but the Recovery Still Has a Ways to Go by Morningstar
- Crude-Market Fundamentals Continue to Tighten, but the Recovery Still Has a Ways to Go by Morningstar
- GPT’s Retail Sales at Front of Pack, but Important Apparel Category Getting Pinched by Online by Morningstar